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background:  ENGAGE AF-TIMI 48 was a randomized controlled trial in 21,105 patients with atrial fibrillation that showed edoxaban was 
at least as efficacious as warfarin (W) while reducing bleeding. We compared results in Japan with the rest of East Asia (EA).
Methods:  We compared the clinical characteristics, time-in-therapeutic range (TTR) for warfarin, and outcomes (stroke or systemic 
embolic events [SEE] and major bleeding). Interaction p-values were used to assess for effect modification of treatment (higher dose 
edoxaban [HDE] vs W; lower dose edoxaban [LDE] vs W) by region with adjustments for baseline differences in patients enrolled in Japan 
vs EA.
results:  Patients in Japan (n=1010) were less likely to be female, taking aspirin or amiodarone at baseline, naïve to W (p<0.001 for each), 
have a prior history of stroke or transient ischemic attack (p=0.02), and more likely to need dose reduction (51% vs 42%, p<0.001). The 
TTR was higher in Japan (72% vs 61%, respectively, p<0.001). Evidence for statistical interactions were observed for HDE vs W by region 
for stroke/SEE (adjusted P-int=0.052) and major bleeding (adjusted P-int=0.048) (Figure). No interactions were observed for LDE vs W.
Conclusion:  Patients in EA had higher rates of stroke/SEE and major bleeding compared to Japan. Differences in relative efficacy and 
safety between edoxaban and warfarin may be related to regional difference in baseline characteristics, prior W experience and/or TTR.
 
